Headshot of Bill  Bangert

Bill Bangert

 |  Archives

I'm a proud Bearcat who translated his broadcasting major in the College Conservatory of Music into a 30-year career in radio, including 17 years in Cincinnati on WLW and WEBN. I write about news and research in the College of Allied Health Sciences, College of Nursing, Pulmonary, Critical Care & Sleep Medicine, Emergency Medicine, Infectious Diseases and Nephrology.

bill.bangert@uc.edu  |  513-558-4519
123 Results

UC COVID-19 research examines the safety and efficacy of immune...

July 15, 2020

Researchers at UC are testing a commonly used drug, called sirolimus, to determine its safety and efficacy in treating hospitalized patients with COVID-19 pneumonia in the trial. The research trial, called Sirolimus Treatment in Hospitalized Patients with COVID-19 Pneumonia (SCOPE), will examine the Food and Drug Administration-approved medication that is most commonly used to prevent organ rejection in patients with kidney transplants. It is also FDA-approved for the treatment of a rare lung disease, LAM.

UC research sees decrease in emergency visits for stroke care

July 9, 2020

Immediately following the announcement of COVID-19 prevention measures in March, the Greater Cincinnati Tristate region saw a nearly 40% decline in patients coming to the hospital in time for emergency stroke care, according to researchers from the University of Cincinnati College of Medicine and Cincinnati Children’s Hospital Medical Center. The researchers are calling for urgent public education to mitigate a potential crisis of stroke patients avoiding needed emergency care due to concerns about COVID-19

UC, UC Health to launch Phase 3 clinical trial for COVID-19...

June 17, 2020

Researchers at the University of Cincinnati and UC Health will host a Phase 3 clinical trial to evaluate the effectiveness of a vaccine for COVID-19, the respiratory illness caused by the novel coronavirus SARS-CoV-2. UC is one of approximately 90 sites across the United States selected for the study, which will administer the vaccine candidate mRNA-1273 to volunteer participants and monitor its efficacy in eliciting an immune response that provides protection from COVID-19.

Load More
Debug Query for this